首页 > 最新文献

Annals of surgery最新文献

英文 中文
The Status of Liver Margin in Perihilar Cholangiocarcinoma: A Multicenter Study. 肝周胆管癌肝边缘的现状:一项多中心研究
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-21 DOI: 10.1097/SLA.0000000000006571
Shuo Jin, Ming-Yu Lin, Can-Hong Xiang, Zhi-Peng Liu, Si-Yuan Wang, Nan Jiang, Li Li, Si-Qiao Shan, Jian-Ping Zeng, Hai-Xin Yin, Tao Zhang, Chang-Zhen Yang, Dong-Liang Yang, Hu Zhou, Zhi-Yu Chen, Jia-Hong Dong

Objective: This study aimed to investigate the prevalence and distribution of carcinoma in the liver margin (LM) of resected perihilar cholangiocarcinoma (pCCA) and establish a method for LM examination.

Background: LM is the largest margin in resected pCCA with undefined status and assessment method.

Methods: 227 pCCA cases underwent major hepatectomy were divided into a discovery cohort (n=101) assessed using serial whole-mount digital large sections (WDLS) combined with small sections, and a control cohort (n=126) assessed using only small sections.

Results: The LM R1 resection rate was 38.6% (39/101) in the discovery cohort and 5.6% (7/126) in the control cohort. WDLS identified more LM R1 cases compared to the small section in the discovery cohort (38.6% vs. 5.9%, P<0.001). R0 patients in the discovery cohort had better overall survival and recurrence-free survival than those in the control cohort (both P<0.05). Additionally, 95% of carcinoma was found within 20 mm of the proximal ductal margin (DM). A proximal DM distance of<5 mm was an independent risk factor for LM R1 resection. Patients with which are more likely to experience R1 compared to those with ≥ 5 mm (P<0.001).

Conclusions: Positive LM was the significant cause for R1 resection of pCCA and the utilization of WDLS improved the diagnostic accuracy of LM. An examination methodology was established, highlighting the necessity of examining LM within a 20 mm radius around the proximal DM, especially in patients with a proximal DM of<5 mm.

研究目的本研究旨在调查切除的肝周胆管癌(pCCA)肝边缘(LM)癌的发生率和分布情况,并建立LM的检查方法:方法:将227例接受肝大部切除术的pCCA病例分为发现队列(n=101)和对照队列(n=126),发现队列采用连续全贴面数字大切片(WDLS)结合小切片进行评估,对照队列仅采用小切片进行评估:发现队列的 LM R1 切除率为 38.6%(39/101),对照队列为 5.6%(7/126)。与发现队列中的小切片相比,WDLS发现了更多的LM R1病例(38.6%对5.9%,PC结论:LM阳性是pCCA R1切除的重要原因,而使用WDLS提高了LM诊断的准确性。我们建立了一套检查方法,强调必须检查近端 DM 周围 20 毫米半径范围内的 LM,尤其是近端 DM 为 0.5 mm 的患者。
{"title":"The Status of Liver Margin in Perihilar Cholangiocarcinoma: A Multicenter Study.","authors":"Shuo Jin, Ming-Yu Lin, Can-Hong Xiang, Zhi-Peng Liu, Si-Yuan Wang, Nan Jiang, Li Li, Si-Qiao Shan, Jian-Ping Zeng, Hai-Xin Yin, Tao Zhang, Chang-Zhen Yang, Dong-Liang Yang, Hu Zhou, Zhi-Yu Chen, Jia-Hong Dong","doi":"10.1097/SLA.0000000000006571","DOIUrl":"https://doi.org/10.1097/SLA.0000000000006571","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the prevalence and distribution of carcinoma in the liver margin (LM) of resected perihilar cholangiocarcinoma (pCCA) and establish a method for LM examination.</p><p><strong>Background: </strong>LM is the largest margin in resected pCCA with undefined status and assessment method.</p><p><strong>Methods: </strong>227 pCCA cases underwent major hepatectomy were divided into a discovery cohort (n=101) assessed using serial whole-mount digital large sections (WDLS) combined with small sections, and a control cohort (n=126) assessed using only small sections.</p><p><strong>Results: </strong>The LM R1 resection rate was 38.6% (39/101) in the discovery cohort and 5.6% (7/126) in the control cohort. WDLS identified more LM R1 cases compared to the small section in the discovery cohort (38.6% vs. 5.9%, P<0.001). R0 patients in the discovery cohort had better overall survival and recurrence-free survival than those in the control cohort (both P<0.05). Additionally, 95% of carcinoma was found within 20 mm of the proximal ductal margin (DM). A proximal DM distance of<5 mm was an independent risk factor for LM R1 resection. Patients with which are more likely to experience R1 compared to those with ≥ 5 mm (P<0.001).</p><p><strong>Conclusions: </strong>Positive LM was the significant cause for R1 resection of pCCA and the utilization of WDLS improved the diagnostic accuracy of LM. An examination methodology was established, highlighting the necessity of examining LM within a 20 mm radius around the proximal DM, especially in patients with a proximal DM of<5 mm.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Status of Liver Margin in Perihilar Cholangiocarcinoma: A Multicenter Study. 肝周胆管癌肝边缘的现状:一项多中心研究
IF 9 1区 医学 Q1 SURGERY Pub Date : 2024-10-21 DOI: 10.1097/sla.0000000000006571
Shuo Jin,Ming-Yu Lin,Can-Hong Xiang,Zhi-Peng Liu,Si-Yuan Wang,Nan Jiang,Li Li,Si-Qiao Shan,Jian-Ping Zeng,Hai-Xin Yin,Tao Zhang,Chang-Zhen Yang,Dong-Liang Yang,Hu Zhou,Zhi-Yu Chen,Jia-Hong Dong
OBJECTIVEThis study aimed to investigate the prevalence and distribution of carcinoma in the liver margin (LM) of resected perihilar cholangiocarcinoma (pCCA) and establish a method for LM examination.BACKGROUNDLM is the largest margin in resected pCCA with undefined status and assessment method.METHODS227 pCCA cases underwent major hepatectomy were divided into a discovery cohort (n=101) assessed using serial whole-mount digital large sections (WDLS) combined with small sections, and a control cohort (n=126) assessed using only small sections.RESULTSThe LM R1 resection rate was 38.6% (39/101) in the discovery cohort and 5.6% (7/126) in the control cohort. WDLS identified more LM R1 cases compared to the small section in the discovery cohort (38.6% vs. 5.9%, P<0.001). R0 patients in the discovery cohort had better overall survival and recurrence-free survival than those in the control cohort (both P<0.05). Additionally, 95% of carcinoma was found within 20 mm of the proximal ductal margin (DM). A proximal DM distance of<5 mm was an independent risk factor for LM R1 resection. Patients with which are more likely to experience R1 compared to those with ≥ 5 mm (P<0.001).CONCLUSIONSPositive LM was the significant cause for R1 resection of pCCA and the utilization of WDLS improved the diagnostic accuracy of LM. An examination methodology was established, highlighting the necessity of examining LM within a 20 mm radius around the proximal DM, especially in patients with a proximal DM of<5 mm.
目的本研究旨在调查切除的肝周胆管癌(pCCA)肝边缘(LM)癌变的发生率和分布情况,并建立LM检查方法。背景LM是切除的pCCA中最大的边缘,其状态和评估方法尚未明确。结果发现队列的 LM R1 切除率为 38.6%(39/101),对照队列为 5.6%(7/126)。在发现队列中,与小切片相比,WDLS发现了更多的LM R1病例(38.6% vs. 5.9%,P<0.001)。发现队列中的 R0 患者的总生存期和无复发生存期均优于对照队列(P<0.05)。此外,95%的癌细胞位于近端导管边缘(DM)20 毫米范围内。近端DM距离小于5毫米是LM R1切除的独立风险因素。结论LM阳性是导致pCCA R1切除的重要原因,使用WDLS提高了LM诊断的准确性。该研究建立了一套检查方法,强调必须检查近端 DM 周围 20 毫米半径内的 LM,尤其是近端 DM 小于 5 毫米的患者。
{"title":"The Status of Liver Margin in Perihilar Cholangiocarcinoma: A Multicenter Study.","authors":"Shuo Jin,Ming-Yu Lin,Can-Hong Xiang,Zhi-Peng Liu,Si-Yuan Wang,Nan Jiang,Li Li,Si-Qiao Shan,Jian-Ping Zeng,Hai-Xin Yin,Tao Zhang,Chang-Zhen Yang,Dong-Liang Yang,Hu Zhou,Zhi-Yu Chen,Jia-Hong Dong","doi":"10.1097/sla.0000000000006571","DOIUrl":"https://doi.org/10.1097/sla.0000000000006571","url":null,"abstract":"OBJECTIVEThis study aimed to investigate the prevalence and distribution of carcinoma in the liver margin (LM) of resected perihilar cholangiocarcinoma (pCCA) and establish a method for LM examination.BACKGROUNDLM is the largest margin in resected pCCA with undefined status and assessment method.METHODS227 pCCA cases underwent major hepatectomy were divided into a discovery cohort (n=101) assessed using serial whole-mount digital large sections (WDLS) combined with small sections, and a control cohort (n=126) assessed using only small sections.RESULTSThe LM R1 resection rate was 38.6% (39/101) in the discovery cohort and 5.6% (7/126) in the control cohort. WDLS identified more LM R1 cases compared to the small section in the discovery cohort (38.6% vs. 5.9%, P<0.001). R0 patients in the discovery cohort had better overall survival and recurrence-free survival than those in the control cohort (both P<0.05). Additionally, 95% of carcinoma was found within 20 mm of the proximal ductal margin (DM). A proximal DM distance of<5 mm was an independent risk factor for LM R1 resection. Patients with which are more likely to experience R1 compared to those with ≥ 5 mm (P<0.001).CONCLUSIONSPositive LM was the significant cause for R1 resection of pCCA and the utilization of WDLS improved the diagnostic accuracy of LM. An examination methodology was established, highlighting the necessity of examining LM within a 20 mm radius around the proximal DM, especially in patients with a proximal DM of<5 mm.","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":"40 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142486348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gaps in Informed Consent for Intimate Exams Under Anesthesia. 麻醉下的亲密检查知情同意书中的漏洞。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-18 DOI: 10.1097/SLA.0000000000006568
Daniel Roy Sadek Habib, George Lin, Alexander Langerman
{"title":"Gaps in Informed Consent for Intimate Exams Under Anesthesia.","authors":"Daniel Roy Sadek Habib, George Lin, Alexander Langerman","doi":"10.1097/SLA.0000000000006568","DOIUrl":"https://doi.org/10.1097/SLA.0000000000006568","url":null,"abstract":"","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Outcomes Following Non-operative Management of Acute Appendicitis: A Population-based Analysis. 急性阑尾炎非手术治疗的长期效果:基于人群的分析
IF 9 1区 医学 Q1 SURGERY Pub Date : 2024-10-16 DOI: 10.1097/sla.0000000000006555
Teagan Telesnicki,Jordan Nantais,Charles De Mestral,Anthony de Buck van Overstraeten,David Gomez
OBJECTIVETo describe long-term re-presentations and interventions following non-operative management (NOM) of acute appendicitis (AA).SUMMARY BACKGROUND DATATrial data suggest NOM of AA carries a substantial risk of subsequent appendectomy, although NOM is increasingly offered to patients. Population-based data is required to understand the real-world long-term course of patients undergoing NOM of AA.METHODSThis population-based cohort study included all adult patients in Ontario, Canada who presented to any emergency department (ED) with AA between 2004-2019. Patients who did not undergo a procedure on index ED presentation or hospital admission were defined as NOM and followed for five years. The cumulative incidence of composite re-presentation or intervention (ED re-presentation, re-admission, emergency, or scheduled appendicitis procedure) was calculated accounting for competing risk of death.RESULTSOf 156,362 patients identified with AA, 13,200 underwent NOM. The cumulative incidence of composite re-presentation or intervention was 33% at 1-year (95%CI 32-33%) and 36% at 5-years (95%CI 36-37%). At 5-years, the incidence of appendicitis-specific ED re-presentation or hospital re-admission was 16% (95%CI 15-16%), the incidence of an emergency procedure for AA was 12% (95%CI 12-13%), and the incidence of scheduled surgery was 21% (95%CI 20-21%). In a subgroup of patients with uncomplicated AA, composite re-presentation or intervention was 28% at 1-year (95%CI 27-29%) and 32% at 5-years (95%CI 32-33%).CONCLUSIONSReal-world estimates of emergency re-presentation with or without urgent surgery following NOM of AA were lower than previously described. Scheduled appendectomy made up an important proportion of long-term interventions following NOM.
目的描述急性阑尾炎(AA)非手术治疗(NOM)后的长期再就诊情况和干预措施。这项基于人群的队列研究纳入了加拿大安大略省 2004-2019 年间因 AA 到急诊科(ED)就诊的所有成年患者。在急诊科就诊或入院时未接受手术的患者被定义为NOM,并随访五年。计算再次就诊或干预(ED 再次就诊、再次入院、急诊或计划阑尾炎手术)的累积发生率,并考虑死亡竞争风险。结果 在 156362 名被确诊为 AA 的患者中,13200 人接受了 NOM。1年后复合再就诊或干预的累计发生率为33%(95%CI 32-33%),5年后为36%(95%CI 36-37%)。5年后,阑尾炎特异性急诊室再次就诊或再次入院的发生率为16%(95%CI 15-16%),AA急诊手术的发生率为12%(95%CI 12-13%),计划手术的发生率为21%(95%CI 20-21%)。在无并发症的 AA 患者亚组中,1 年后再次就诊或干预的复合发生率为 28%(95%CI 27-29%),5 年后为 32%(95%CI 32-33%)。在NOM后的长期干预中,计划中的阑尾切除术占了很大比例。
{"title":"Long-term Outcomes Following Non-operative Management of Acute Appendicitis: A Population-based Analysis.","authors":"Teagan Telesnicki,Jordan Nantais,Charles De Mestral,Anthony de Buck van Overstraeten,David Gomez","doi":"10.1097/sla.0000000000006555","DOIUrl":"https://doi.org/10.1097/sla.0000000000006555","url":null,"abstract":"OBJECTIVETo describe long-term re-presentations and interventions following non-operative management (NOM) of acute appendicitis (AA).SUMMARY BACKGROUND DATATrial data suggest NOM of AA carries a substantial risk of subsequent appendectomy, although NOM is increasingly offered to patients. Population-based data is required to understand the real-world long-term course of patients undergoing NOM of AA.METHODSThis population-based cohort study included all adult patients in Ontario, Canada who presented to any emergency department (ED) with AA between 2004-2019. Patients who did not undergo a procedure on index ED presentation or hospital admission were defined as NOM and followed for five years. The cumulative incidence of composite re-presentation or intervention (ED re-presentation, re-admission, emergency, or scheduled appendicitis procedure) was calculated accounting for competing risk of death.RESULTSOf 156,362 patients identified with AA, 13,200 underwent NOM. The cumulative incidence of composite re-presentation or intervention was 33% at 1-year (95%CI 32-33%) and 36% at 5-years (95%CI 36-37%). At 5-years, the incidence of appendicitis-specific ED re-presentation or hospital re-admission was 16% (95%CI 15-16%), the incidence of an emergency procedure for AA was 12% (95%CI 12-13%), and the incidence of scheduled surgery was 21% (95%CI 20-21%). In a subgroup of patients with uncomplicated AA, composite re-presentation or intervention was 28% at 1-year (95%CI 27-29%) and 32% at 5-years (95%CI 32-33%).CONCLUSIONSReal-world estimates of emergency re-presentation with or without urgent surgery following NOM of AA were lower than previously described. Scheduled appendectomy made up an important proportion of long-term interventions following NOM.","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":"2 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Resection for Pancreas Cancer - 10-year Experience from a Single High Volume-center. 胰腺癌血管切除术--来自一家高容量中心的十年经验。
IF 9 1区 医学 Q1 SURGERY Pub Date : 2024-10-16 DOI: 10.1097/sla.0000000000006567
David Henault,Holden Kunde,Cody Zatzman,Daniela Bevacqua,Danielle LA Arshinoff,Sean P Cleary,Laura A Dawson,Elena Elimova,Robert Grant,Ali Hosni,Raymond W Jang,Jennifer J Knox,Aruz Mesci,Malcolm Moore,Carol-Anne E Moulton,Trevor W Reichman,Chaya Shwaartz,Erica S Tsang,Ian D McGilvray,Steven Gallinger
OBJECTIVE BACKGROUNDCombined pancreatic and vascular resections are increasingly performed for pancreatic ductal adenocarcinoma (PDAC). We evaluated the outcomes after pancreatectomy with non-vascular resection (NVR), venous resection (VR), and arterial resection (AR).METHODSRetrospective review (2011-2023) of 715 PDAC patients treated with curative-intent surgery. Associations among clinicopathological data, perioperative therapy, time to recurrence (TTR), and overall survival (OS) were evaluated.RESULTSInitial staging revealed 533 resectable, 98 borderline, and 84 locally advanced PDAC cases. Pancreaticoduodenectomy was the most common procedure (n=467). NVR was performed in 351 (58.2%) patients, VR in 181 (30.0%), and AR in 70 (11.8%). The median TTR and OS did not significantly differ according to the initial staging or type of pancreas resection. Median TTR and OS were significantly shorter for VR (14.5 and 22.7 mo) compared to NVR (18.6 and 30.5 mo, P<0.001) and AR (20.6 and 30.9 mo, P=0.004 and P=0.017). Chemotherapy or chemoradiation significantly prolonged TTR (20.1 vs. 10.2 mo, P<0.001 and 25.3 vs. 16.4 mo, P<0.001) and OS (31.5 vs. 17.2 mo, P<0.001 and 35.5 vs. 27.5 mo, P=0.030). AR was associated with higher 90-day mortality rates. In the multivariable analysis, vascular resection was not associated with OS. Perioperative therapy, pathological N0 status, and absence of perineural invasion were the key predictors of longer TTR and OS.CONCLUSIONSPancreatectomy with AR was not associated with worse oncological outcomes when controlling for perioperative therapy. However, AR was associated with higher 90-day mortality rates. Patient selection is crucial when performing AR in patients with PDAC.
目的 背景胰腺导管腺癌(PDAC)越来越多地采用胰腺和血管联合切除术。我们评估了非血管切除术(NVR)、静脉切除术(VR)和动脉切除术(AR)胰腺切除术后的预后。结果初步分期显示有533例可切除、98例边缘和84例局部晚期PDAC病例。胰十二指肠切除术是最常见的手术(n=467)。351例(58.2%)患者进行了NVR,181例(30.0%)进行了VR,70例(11.8%)进行了AR。中位 TTR 和 OS 与初始分期或胰腺切除类型无明显差异。与NVR(18.6和30.5个月,P<0.001)和AR(20.6和30.9个月,P=0.004和P=0.017)相比,VR(14.5和22.7个月)的中位TTR和OS明显较短。化疗或放疗可明显延长TTR(20.1个月对10.2个月,P<0.001;25.3个月对16.4个月,P<0.001)和OS(31.5个月对17.2个月,P<0.001;35.5个月对27.5个月,P=0.030)。AR与较高的90天死亡率相关。在多变量分析中,血管切除与OS无关。结论在控制围手术期治疗的情况下,AR胰切除术与较差的肿瘤预后无关。然而,AR与较高的90天死亡率有关。在对PDAC患者进行AR手术时,患者的选择至关重要。
{"title":"Vascular Resection for Pancreas Cancer - 10-year Experience from a Single High Volume-center.","authors":"David Henault,Holden Kunde,Cody Zatzman,Daniela Bevacqua,Danielle LA Arshinoff,Sean P Cleary,Laura A Dawson,Elena Elimova,Robert Grant,Ali Hosni,Raymond W Jang,Jennifer J Knox,Aruz Mesci,Malcolm Moore,Carol-Anne E Moulton,Trevor W Reichman,Chaya Shwaartz,Erica S Tsang,Ian D McGilvray,Steven Gallinger","doi":"10.1097/sla.0000000000006567","DOIUrl":"https://doi.org/10.1097/sla.0000000000006567","url":null,"abstract":"OBJECTIVE BACKGROUNDCombined pancreatic and vascular resections are increasingly performed for pancreatic ductal adenocarcinoma (PDAC). We evaluated the outcomes after pancreatectomy with non-vascular resection (NVR), venous resection (VR), and arterial resection (AR).METHODSRetrospective review (2011-2023) of 715 PDAC patients treated with curative-intent surgery. Associations among clinicopathological data, perioperative therapy, time to recurrence (TTR), and overall survival (OS) were evaluated.RESULTSInitial staging revealed 533 resectable, 98 borderline, and 84 locally advanced PDAC cases. Pancreaticoduodenectomy was the most common procedure (n=467). NVR was performed in 351 (58.2%) patients, VR in 181 (30.0%), and AR in 70 (11.8%). The median TTR and OS did not significantly differ according to the initial staging or type of pancreas resection. Median TTR and OS were significantly shorter for VR (14.5 and 22.7 mo) compared to NVR (18.6 and 30.5 mo, P<0.001) and AR (20.6 and 30.9 mo, P=0.004 and P=0.017). Chemotherapy or chemoradiation significantly prolonged TTR (20.1 vs. 10.2 mo, P<0.001 and 25.3 vs. 16.4 mo, P<0.001) and OS (31.5 vs. 17.2 mo, P<0.001 and 35.5 vs. 27.5 mo, P=0.030). AR was associated with higher 90-day mortality rates. In the multivariable analysis, vascular resection was not associated with OS. Perioperative therapy, pathological N0 status, and absence of perineural invasion were the key predictors of longer TTR and OS.CONCLUSIONSPancreatectomy with AR was not associated with worse oncological outcomes when controlling for perioperative therapy. However, AR was associated with higher 90-day mortality rates. Patient selection is crucial when performing AR in patients with PDAC.","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":"10 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142448048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical value of Intratumor Heterogeneity. 胰腺新辅助切除术后胰腺导管腺癌的形态学特征及瘤内异质性的临床价值
IF 9 1区 医学 Q1 SURGERY Pub Date : 2024-10-15 DOI: 10.1097/sla.0000000000006565
Gabriella Lionetto,Paola Mattiolo,Calogero Ciulla,Giulia Savegnago,Fabio Casciani,Matteo De Pastena,Salvatore Paiella,Antonio Pea,Alessandro Esposito,Anna Crovetto,Massimo Donadelli,Carlotta Franzina,Matteo Fassan,Aldo Scarpa,Roberto Salvia,Giuseppe Malleo,Claudio Luchini
OBJECTIVETo evaluate the morphologic landscape of pancreatic ductal adenocarcinoma (PDAC), intratumor spatial heterogeneity, and the resulting clinical impact following post-neoadjuvant pancreatectomy.SUMMARY BACKGROUND DATAThe clinical value of PDAC morphologic subtypes and intratumor spatial heterogeneity post-treatment remains an open issue.MATERIALS AND METHODSThe study cohort included patients who underwent post-neoadjuvant pancreatectomy for PDAC at the University of Verona Hospital Trust between 2013 and 2019. All hematoxylin and eosin-stained slides were reviewed to assess PDAC histomorphology and intratumor heterogeneity. The relationship with other clinicopathological variables, overall survival (OS), and recurrence-free (RFS) survival was evaluated using standard statistics.RESULTSThe study cohort included 400 patients. Histological revision identified ten different morphologic subtypes. Gland-forming PDAC with a conventional pattern was the most frequently identified subtype (41.8%). Overall, 247 tumors (61.7%) showed only one histological pattern and were classified as homogeneous, whereas 153 (38.3%) showed different morphologies and were classified as heterogeneous tumors. The median post-resection survival was 30.1 months (95%CI 26.6-33.5). There was a substantial survival variability according to the morphologic subtype, ranging from 19.1 months in the gyriform subtype to 47.0 months in the papillary subtype. Tumors with a heterogeneous morphology displayed a higher rate of nodal metastases, worse tumor regression metrics, and worse oncologic outcomes relative to spatially homogeneous tumors.DISCUSSIONThis paper provided a morphological taxonomy of residual tumors following post-neoadjuvant pancreatectomy for PDAC. The morphologic subtype and intratumor spatial heterogeneity have relevant prognostic implications and could be included in the pathology report to complement regression metrics.
目的评估新辅助治疗后胰腺切除术后胰腺导管腺癌(PDAC)的形态特征、肿瘤内空间异质性以及由此产生的临床影响。摘要背景资料PDAC形态亚型和治疗后肿瘤内空间异质性的临床价值仍是一个悬而未决的问题。材料与方法研究队列包括2013年至2019年期间在维罗纳大学医院信托基金接受新辅助治疗后胰腺切除术治疗PDAC的患者。对所有苏木精和伊红染色的切片进行了审查,以评估 PDAC 组织形态学和肿瘤内异质性。使用标准统计学方法评估了与其他临床病理变量、总生存期(OS)和无复发生存期(RFS)之间的关系。组织学修订确定了十种不同的形态亚型。具有传统模式的腺形成 PDAC 是最常见的亚型(41.8%)。总体而言,247 例肿瘤(61.7%)只显示一种组织学形态,被归类为同种肿瘤,而 153 例肿瘤(38.3%)显示不同形态,被归类为异种肿瘤。切除后的中位生存期为 30.1 个月(95%CI 26.6-33.5)。形态亚型的生存期差异很大,从回形亚型的19.1个月到乳头亚型的47.0个月不等。与空间均一的肿瘤相比,形态异型的肿瘤显示出更高的结节转移率、更差的肿瘤消退指标和更差的肿瘤学预后。形态亚型和瘤内空间异质性对预后有相关影响,可纳入病理报告以补充回归指标。
{"title":"Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical value of Intratumor Heterogeneity.","authors":"Gabriella Lionetto,Paola Mattiolo,Calogero Ciulla,Giulia Savegnago,Fabio Casciani,Matteo De Pastena,Salvatore Paiella,Antonio Pea,Alessandro Esposito,Anna Crovetto,Massimo Donadelli,Carlotta Franzina,Matteo Fassan,Aldo Scarpa,Roberto Salvia,Giuseppe Malleo,Claudio Luchini","doi":"10.1097/sla.0000000000006565","DOIUrl":"https://doi.org/10.1097/sla.0000000000006565","url":null,"abstract":"OBJECTIVETo evaluate the morphologic landscape of pancreatic ductal adenocarcinoma (PDAC), intratumor spatial heterogeneity, and the resulting clinical impact following post-neoadjuvant pancreatectomy.SUMMARY BACKGROUND DATAThe clinical value of PDAC morphologic subtypes and intratumor spatial heterogeneity post-treatment remains an open issue.MATERIALS AND METHODSThe study cohort included patients who underwent post-neoadjuvant pancreatectomy for PDAC at the University of Verona Hospital Trust between 2013 and 2019. All hematoxylin and eosin-stained slides were reviewed to assess PDAC histomorphology and intratumor heterogeneity. The relationship with other clinicopathological variables, overall survival (OS), and recurrence-free (RFS) survival was evaluated using standard statistics.RESULTSThe study cohort included 400 patients. Histological revision identified ten different morphologic subtypes. Gland-forming PDAC with a conventional pattern was the most frequently identified subtype (41.8%). Overall, 247 tumors (61.7%) showed only one histological pattern and were classified as homogeneous, whereas 153 (38.3%) showed different morphologies and were classified as heterogeneous tumors. The median post-resection survival was 30.1 months (95%CI 26.6-33.5). There was a substantial survival variability according to the morphologic subtype, ranging from 19.1 months in the gyriform subtype to 47.0 months in the papillary subtype. Tumors with a heterogeneous morphology displayed a higher rate of nodal metastases, worse tumor regression metrics, and worse oncologic outcomes relative to spatially homogeneous tumors.DISCUSSIONThis paper provided a morphological taxonomy of residual tumors following post-neoadjuvant pancreatectomy for PDAC. The morphologic subtype and intratumor spatial heterogeneity have relevant prognostic implications and could be included in the pathology report to complement regression metrics.","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":"13 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes among Patients with End-Stage Kidney Disease and Chronic Limb-Threatening Ischemia: A Population-based Cohort Study. 终末期肾病和慢性肢体危重缺血患者的预后:基于人群的队列研究
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-15 DOI: 10.1097/SLA.0000000000006566
Samir K Shah, Dan Neal, Terrie Vasilopoulos, Mark Segal, Scott Berceli, Joel S Weissman

Objective: To understand mortality and secondary outcomes in patients with both end-stage kidney disease (ESKD) and chronic limb-threatening ischemia (CLTI) after no procedural treatment, primary amputation, endovascular treatment, and open surgery.

Summary background data: ESKD and CLTI commonly cooccur and limited prior work has demonstrated poor outcomes including one-year survival despite treatment.

Methods: We conducted a retrospective national cohort study of United States Renal Data System data from January 1, 2016 to December 31, 2019 to determine mortality, major postoperative complications, and other outcomes. We performed an exploratory analysis comparing two-year survival by treatment using propensity matching.

Results: Of 1,876,652 records with a CLTI diagnosis, we identified 3,908 patients with ESKD and an incident CLTI diagnosis. Mean age at CLTI diagnosis was 65.7 years and 2,405 (61.5%) were male. 2,696 (69.0%) had no procedural treatment, 609 (15.6%) had major limb amputation, 439 (11.2%) had endovascular treatment, and 164 (4.2%) had open surgery. There was 44.9% mortality at one year, along with 41.8% major postoperative complications and 52.6% readmissions at 90 days. Comparing two-year survival, we found no differences between the amputation and endovascular cohorts (P=0.08) and between endovascular and open (P=.06). There was superior two-year survival in the open surgery cohort compared to the amputation cohort (P=0.002).

Conclusions: Patients living with both ESKD and CLTI experience poor outcomes irrespective of treatment. Exploratory analyses demonstrated that two-year survival among the three principal procedural treatments was similar except for superior survival among patients undergoing open therapy compared to primary amputation.

目的了解终末期肾病(ESKD)和慢性肢体缺血(CLTI)患者在未接受程序性治疗、初次截肢、血管内治疗和开放手术后的死亡率和次要预后:背景数据摘要:ESKD 和 CLTI 通常同时存在,而之前有限的研究表明,尽管进行了治疗,但疗效不佳,包括一年的存活率:我们对美国肾脏数据系统 2016 年 1 月 1 日至 2019 年 12 月 31 日的数据进行了一项回顾性全国队列研究,以确定死亡率、主要术后并发症和其他结果。我们采用倾向匹配法进行了一项探索性分析,比较了不同治疗方法的两年生存率:在1,876,652份诊断为CLTI的记录中,我们发现了3,908名患有ESKD并被诊断为CLTI的患者。确诊 CLTI 时的平均年龄为 65.7 岁,其中 2,405 人(61.5%)为男性。2,696名患者(69.0%)未接受手术治疗,609名患者(15.6%)接受了大肢截肢手术,439名患者(11.2%)接受了血管内治疗,164名患者(4.2%)接受了开放手术。一年的死亡率为 44.9%,主要术后并发症为 41.8%,90 天再入院率为 52.6%。在比较两年存活率时,我们发现截肢组和血管内手术组之间没有差异(P=0.08),血管内手术组和开放手术组之间也没有差异(P=0.06)。与截肢组相比,开放手术组的两年生存率更高(P=0.002):结论:同时患有ESKD和CLTI的患者无论接受何种治疗,都会出现不良预后。探索性分析表明,三种主要手术治疗方法的两年生存率相似,但接受开放式治疗的患者的生存率高于接受原发性截肢的患者。
{"title":"Outcomes among Patients with End-Stage Kidney Disease and Chronic Limb-Threatening Ischemia: A Population-based Cohort Study.","authors":"Samir K Shah, Dan Neal, Terrie Vasilopoulos, Mark Segal, Scott Berceli, Joel S Weissman","doi":"10.1097/SLA.0000000000006566","DOIUrl":"https://doi.org/10.1097/SLA.0000000000006566","url":null,"abstract":"<p><strong>Objective: </strong>To understand mortality and secondary outcomes in patients with both end-stage kidney disease (ESKD) and chronic limb-threatening ischemia (CLTI) after no procedural treatment, primary amputation, endovascular treatment, and open surgery.</p><p><strong>Summary background data: </strong>ESKD and CLTI commonly cooccur and limited prior work has demonstrated poor outcomes including one-year survival despite treatment.</p><p><strong>Methods: </strong>We conducted a retrospective national cohort study of United States Renal Data System data from January 1, 2016 to December 31, 2019 to determine mortality, major postoperative complications, and other outcomes. We performed an exploratory analysis comparing two-year survival by treatment using propensity matching.</p><p><strong>Results: </strong>Of 1,876,652 records with a CLTI diagnosis, we identified 3,908 patients with ESKD and an incident CLTI diagnosis. Mean age at CLTI diagnosis was 65.7 years and 2,405 (61.5%) were male. 2,696 (69.0%) had no procedural treatment, 609 (15.6%) had major limb amputation, 439 (11.2%) had endovascular treatment, and 164 (4.2%) had open surgery. There was 44.9% mortality at one year, along with 41.8% major postoperative complications and 52.6% readmissions at 90 days. Comparing two-year survival, we found no differences between the amputation and endovascular cohorts (P=0.08) and between endovascular and open (P=.06). There was superior two-year survival in the open surgery cohort compared to the amputation cohort (P=0.002).</p><p><strong>Conclusions: </strong>Patients living with both ESKD and CLTI experience poor outcomes irrespective of treatment. Exploratory analyses demonstrated that two-year survival among the three principal procedural treatments was similar except for superior survival among patients undergoing open therapy compared to primary amputation.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Assessment of Outcomes: Abdominal Drain vs. No Abdominal Drain after Left Pancreatectomy-A Systematic Review and Meta-Analysis. 结果的比较评估:左侧胰腺切除术后腹腔引流管与无腹腔引流管的比较--系统性回顾和 Meta 分析。
IF 9 1区 医学 Q1 SURGERY Pub Date : 2024-10-14 DOI: 10.1097/sla.0000000000006564
Aleena Ahmed,Maurish Fatima,Muhammad Hammad Khan,Muhammad Hashim Faisal,Ayesha Sehar,Muhammad Jahanzaib Khan,Hassan Aziz
OBJECTIVEThis systematic review and meta-analysis aimed to compare outcomes between abdominal drain placement and no drain placement post-pancreatectomy.BACKGROUNDLeft pancreatectomy (LP) is a surgical procedure commonly employed for various pancreatic conditions, often associated with postoperative complications like post-operative pancreatic fistula (POPF). While routine abdominal drainage following LP has been standard practice, recent evidence suggests potential benefits of omitting this approach.METHODSA comprehensive search was conducted on PubMed, Cochrane, and Embase from inception up to 15 March 2024, yielding nine studies comprising 15,817 patients. Data were extracted from randomized and non-randomized studies reporting primary and secondary outcomes. The analysis was performed in Revman. Risk ratios were calculated with 95% confidence intervals, and a P-value of <0.05 was considered statistically significant.RESULTSA total of 13,081 patients underwent drain placement after left pancreatectomy, and 2,736 patients were included in the no-drain group. Out of the total, 45.1% (n=7140) patients were male, with 45.9% (n=6012) males in the drain group and 41.2% (n=1128) males in the no-drain group. Major morbidity, defined as Clavien-Dindo grade ≥III complications, was significantly lower in the no-drain group (relative risk [RR]: 0.77, 95% confidence interval [CI]: 0.64-0.93, P=0.006). Similarly, lower rates of postoperative pancreatic fistula (POPF) (RR: 0.51, 95% CI: 0.38-0.67, P<0.00001), readmission (RR: 0.75, 95% CI: 0.59-0.96, P=0.02), and surgical site infections (RR: 0.82, 95% CI: 0.70-0.95, P=0.009) were observed in the no-drain group. Additionally, a shorter length of hospital stay was noted in this group (mean difference MD: -1.65, 95% CI: -2.50 to -0.81, P=0.0001).CONCLUSIONSOmitting routine drainage after left pancreatectomy is associated with reduced complications and shorter hospital stays, supporting its potential benefits in improving postoperative outcomes.
目的本系统综述和荟萃分析旨在比较胰腺切除术后放置腹腔引流管和不放置引流管的结果。背景左侧胰腺切除术(LP)是一种常用于治疗各种胰腺疾病的外科手术,通常与术后并发症(如术后胰瘘(POPF))相关。方法在 PubMed、Cochrane 和 Embase 上进行了从开始到 2024 年 3 月 15 日的全面检索,共获得 9 项研究,包括 15,817 名患者。数据提取自报告主要和次要结果的随机和非随机研究。分析在 Revman 中进行。结果共有 13081 名患者在左侧胰腺切除术后接受了引流管置入术,2736 名患者被纳入无引流管组。其中男性患者占 45.1%(n=7140),引流管组男性患者占 45.9%(n=6012),无引流管组男性患者占 41.2%(n=1128)。无引流组的主要发病率(定义为 Clavien-Dindo ≥III 级并发症)显著较低(相对风险 [RR]:0.77,95% 置信区间 [CI]:0.64-0.93,P=0.006)。同样,无引流组术后胰瘘(POPF)(RR:0.51,95% CI:0.38-0.67,P<0.00001)、再入院(RR:0.75,95% CI:0.59-0.96,P=0.02)和手术部位感染(RR:0.82,95% CI:0.70-0.95,P=0.009)的发生率也较低。结论左侧胰腺切除术后常规引流与并发症减少和住院时间缩短有关,支持其在改善术后预后方面的潜在益处。
{"title":"Comparative Assessment of Outcomes: Abdominal Drain vs. No Abdominal Drain after Left Pancreatectomy-A Systematic Review and Meta-Analysis.","authors":"Aleena Ahmed,Maurish Fatima,Muhammad Hammad Khan,Muhammad Hashim Faisal,Ayesha Sehar,Muhammad Jahanzaib Khan,Hassan Aziz","doi":"10.1097/sla.0000000000006564","DOIUrl":"https://doi.org/10.1097/sla.0000000000006564","url":null,"abstract":"OBJECTIVEThis systematic review and meta-analysis aimed to compare outcomes between abdominal drain placement and no drain placement post-pancreatectomy.BACKGROUNDLeft pancreatectomy (LP) is a surgical procedure commonly employed for various pancreatic conditions, often associated with postoperative complications like post-operative pancreatic fistula (POPF). While routine abdominal drainage following LP has been standard practice, recent evidence suggests potential benefits of omitting this approach.METHODSA comprehensive search was conducted on PubMed, Cochrane, and Embase from inception up to 15 March 2024, yielding nine studies comprising 15,817 patients. Data were extracted from randomized and non-randomized studies reporting primary and secondary outcomes. The analysis was performed in Revman. Risk ratios were calculated with 95% confidence intervals, and a P-value of <0.05 was considered statistically significant.RESULTSA total of 13,081 patients underwent drain placement after left pancreatectomy, and 2,736 patients were included in the no-drain group. Out of the total, 45.1% (n=7140) patients were male, with 45.9% (n=6012) males in the drain group and 41.2% (n=1128) males in the no-drain group. Major morbidity, defined as Clavien-Dindo grade ≥III complications, was significantly lower in the no-drain group (relative risk [RR]: 0.77, 95% confidence interval [CI]: 0.64-0.93, P=0.006). Similarly, lower rates of postoperative pancreatic fistula (POPF) (RR: 0.51, 95% CI: 0.38-0.67, P<0.00001), readmission (RR: 0.75, 95% CI: 0.59-0.96, P=0.02), and surgical site infections (RR: 0.82, 95% CI: 0.70-0.95, P=0.009) were observed in the no-drain group. Additionally, a shorter length of hospital stay was noted in this group (mean difference MD: -1.65, 95% CI: -2.50 to -0.81, P=0.0001).CONCLUSIONSOmitting routine drainage after left pancreatectomy is associated with reduced complications and shorter hospital stays, supporting its potential benefits in improving postoperative outcomes.","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":"55 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142436033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shareholder Considerations in Healthcare. 医疗保健领域的股东考虑因素。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-14 DOI: 10.1097/SLA.0000000000006560
Niyum Gandhi
{"title":"Shareholder Considerations in Healthcare.","authors":"Niyum Gandhi","doi":"10.1097/SLA.0000000000006560","DOIUrl":"10.1097/SLA.0000000000006560","url":null,"abstract":"","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population-Based Cohort Study on Treatment and Overall Survival of Patients Clinically Diagnosed With T1 Ampullary Cancer. 临床诊断为 T1 级胰腺癌患者的治疗和总生存期人群队列研究
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-14 DOI: 10.1097/SLA.0000000000006563
Anouk J de Wilde, Evelien J M de Jong, Marco J Bruno, Marc G Besselink, Lydia G M van der Geest, Sandra M E Geurts, Bas Groot Koerkamp, Ignace H J T de Hingh, Vincent E de Meijer, Razvan L Miclea, Jan-Werner Poley, Iryna V Samarska, Hjalmar C van Santvoort, Martijn W J Stommel, Rogier P Voermans, Steven W M Olde Damink, Judith de Vos-Geelen, Stefan A W Bouwense

Objective: To evaluate treatment outcomes, overall survival (OS), and prognostic factors for OS in patients diagnosed with T1 ampullary cancer.

Background: Ampullary cancer is a rare gastrointestinal malignancy with limited data from large cohorts, especially regarding T1 disease.

Methods: Patients diagnosed with clinical (c) T1 ampullary cancer and patients with pathological (p) T1 in the case of cTx were included from the Netherlands Cancer Registry (2014-2021). Primary endpoint was OS, analyzed using the Kaplan-Meier estimator. Multivariable Cox proportional hazards regression was used to identify OS predictors.

Results: Overall, 244 patients with cT1 ampullary cancer were included, of whom 75% (n=184) underwent resection. Among these, 68% (n=125) were upstaged to a higher pathologically T classification (pT2:40%, pT3:22%, pT4:5%). Similarly, cN0 was upstaged to pN1 in 47% of patients (n=87). Next, 100 patients with pT1 and cTx ampullary cancer were included, making a total of 159 patients with pT1 tumor. 92% (146/159) underwent pancreatoduodenectomy while 8% (13/159) underwent endoscopic or local surgical resection. The 1- and 5-year OS for cT1N0 ampullary cancer were 72% and 36%, while for pT1N0 they were 94% and 75%. Independent poor prognostic factors for OS were pN1 classification (HR 2.12; 95%CI 1.15-3.94, P=0.017), pNx classification (i.e. locally resected patients) (HR 2.82; 95%CI 1.22-6.55, P=0.016), and poorly differentiated tumors (HR 4.05; 95%CI 1.33-12.40, P=0.014).

Conclusion: In patients with cT1 ampullary cancer, more than two-thirds had a pathologically higher T classification, and almost half had a pathologically higher N classification. These findings suggest that pancreatoduodenectomy is recommended for cT1 ampullary cancer.

摘要评估确诊为T1型鞍状腺癌患者的治疗效果、总生存率(OS)以及OS的预后因素:背景:胰腺癌是一种罕见的胃肠道恶性肿瘤,来自大型队列的数据有限,尤其是关于T1疾病的数据:方法:从荷兰癌症登记处(2014-2021年)纳入临床(c)T1型胰腺癌患者和病理(p)T1型胰腺癌患者。主要终点为OS,采用Kaplan-Meier估计器进行分析。多变量考克斯比例危险回归用于确定OS预测因素:共纳入244名cT1级胰腺癌患者,其中75%(184人)接受了切除手术。在这些患者中,68%(n=125)的病理T分级更高(pT2:40%,pT3:22%,pT4:5%)。同样,47% 的患者(87 人)的 cN0 升为 pN1。接下来,100 名患有 pT1 和 cTx 的膀胱癌患者被纳入其中,这样共有 159 名患者患有 pT1 肿瘤。92%的患者(146/159)接受了胰十二指肠切除术,8%的患者(13/159)接受了内镜或局部手术切除。cT1N0胰壶腹癌的1年和5年生存率分别为72%和36%,而pT1N0胰壶腹癌的1年和5年生存率分别为94%和75%。OS的独立不良预后因素是pN1分级(HR 2.12;95%CI 1.15-3.94,P=0.017)、pNx分级(即局部切除患者)(HR 2.82;95%CI 1.22-6.55,P=0.016)和分化差的肿瘤(HR 4.05;95%CI 1.33-12.40,P=0.014):结论:在cT1级胰瓿癌患者中,超过三分之二的患者病理分级为较高的T级,近一半的患者病理分级为较高的N级。这些研究结果表明,建议对 cT1 ampullary 癌进行胰十二指肠切除术。
{"title":"Population-Based Cohort Study on Treatment and Overall Survival of Patients Clinically Diagnosed With T1 Ampullary Cancer.","authors":"Anouk J de Wilde, Evelien J M de Jong, Marco J Bruno, Marc G Besselink, Lydia G M van der Geest, Sandra M E Geurts, Bas Groot Koerkamp, Ignace H J T de Hingh, Vincent E de Meijer, Razvan L Miclea, Jan-Werner Poley, Iryna V Samarska, Hjalmar C van Santvoort, Martijn W J Stommel, Rogier P Voermans, Steven W M Olde Damink, Judith de Vos-Geelen, Stefan A W Bouwense","doi":"10.1097/SLA.0000000000006563","DOIUrl":"https://doi.org/10.1097/SLA.0000000000006563","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate treatment outcomes, overall survival (OS), and prognostic factors for OS in patients diagnosed with T1 ampullary cancer.</p><p><strong>Background: </strong>Ampullary cancer is a rare gastrointestinal malignancy with limited data from large cohorts, especially regarding T1 disease.</p><p><strong>Methods: </strong>Patients diagnosed with clinical (c) T1 ampullary cancer and patients with pathological (p) T1 in the case of cTx were included from the Netherlands Cancer Registry (2014-2021). Primary endpoint was OS, analyzed using the Kaplan-Meier estimator. Multivariable Cox proportional hazards regression was used to identify OS predictors.</p><p><strong>Results: </strong>Overall, 244 patients with cT1 ampullary cancer were included, of whom 75% (n=184) underwent resection. Among these, 68% (n=125) were upstaged to a higher pathologically T classification (pT2:40%, pT3:22%, pT4:5%). Similarly, cN0 was upstaged to pN1 in 47% of patients (n=87). Next, 100 patients with pT1 and cTx ampullary cancer were included, making a total of 159 patients with pT1 tumor. 92% (146/159) underwent pancreatoduodenectomy while 8% (13/159) underwent endoscopic or local surgical resection. The 1- and 5-year OS for cT1N0 ampullary cancer were 72% and 36%, while for pT1N0 they were 94% and 75%. Independent poor prognostic factors for OS were pN1 classification (HR 2.12; 95%CI 1.15-3.94, P=0.017), pNx classification (i.e. locally resected patients) (HR 2.82; 95%CI 1.22-6.55, P=0.016), and poorly differentiated tumors (HR 4.05; 95%CI 1.33-12.40, P=0.014).</p><p><strong>Conclusion: </strong>In patients with cT1 ampullary cancer, more than two-thirds had a pathologically higher T classification, and almost half had a pathologically higher N classification. These findings suggest that pancreatoduodenectomy is recommended for cT1 ampullary cancer.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1